Recon: FDA uncovers GMP issues at Catalent’s Belgium facility; AstraZeneca’s Fasenra misses goal in late-stage eosinophilic esophagitis trial
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy